This week, six biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Cancer Genetics, Inc. (CGIX) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. In Portfolio Grader’s specific subcategories of Earnings Momentum and Sales Growth, CGIX also gets A’s. For more information, get Portfolio Grader’s complete analysis of CGIX stock.

La Jolla Pharmaceutical Company (LJPC) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

Incyte Corporation (INCY) is seeing ratings go up from a C last week to a B this week. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

Ambit Biosciences Corp. (AMBI) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Progenics Pharmaceuticals, Inc.’s (PGNX) ratings are looking better this week, moving up to a B from last week’s C. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

This week, Celladon Corporation (CLDN) pushes up from a B to an A rating. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.